共 41 条
[22]
CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles
[J].
PHARMACOGENETICS,
1998, 8 (06)
:529-541
[23]
EVIDENCE FOR A DISSOCIATION IN THE CONTROL OF SPARTEINE, DEBRISOQUINE AND METOPROLOL METABOLISM IN NIGERIANS
[J].
PHARMACOGENETICS,
1992, 2 (02)
:89-92
[27]
Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6
[J].
PHARMACOGENETICS,
2000, 10 (07)
:577-581
[28]
Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations
[J].
PHARMACOGENETICS,
2003, 13 (04)
:207-218
[29]
Rogan PK, 1998, HUM MUTAT, V12, P153, DOI 10.1002/(SICI)1098-1004(1998)12:3<153::AID-HUMU3>3.3.CO
[30]
2-O